Table 1 Baseline demographic and clinical characteristics before and after implementation of standardized outcome monitoring and CDS for polyarticular JIA
All N = 152 | Pre-intervention N = 54 | Phase I N = 98 | p-value | |
|---|---|---|---|---|
Incident diagnosis, n (%) | 46 (30) | 15 (28) | 31 (32) | 0.62 |
Age, median (IQR) | 14.9 (12.2–17.4) | 15.5 (12.1–16.8) | 14.8 (12.2–17.5) | 0.79 |
Male, n (%) | 98 (64) | 35 (65) | 63 (64) | 0.95 |
Race (Non-white) n (%) | 23 (15) | 7 (13) | 16 (16) | 0.58 |
Hispanic Ethnicity, n (%) | 9 (5) | 4 (7) | 5 (5) | 0.56 |
Public insurance, n (%) | 67 (44) | 17 (31) | 50 (51) | 0.02 |
ILAR Criteria for ERA | ||||
•Presence of arthritis, n (%) | 131 (86) | 47 (87) | 84 (86) | 0.82 |
•Presence of enthesitis, n (%) | 129 (85) | 48 (89) | 81 (83) | 0.31 |
•Arthritis in a male > 6 year, n (%) | 68 (45) | 26 (48) | 42,843) | 0.53 |
•SIJ tenderness, n (%) | 64 (42) | 24 (44) | 40 (41) | 0.67 |
•Acute anterior uveitis, n (%) | 14 (9) | 4 (7) | 10 (10) | 0.57 |
•Family history of HLA-B27 related disease, n (%) | 12 (8) | 5 (9) | 7 (7) | 0.64 |
Baseline paina, median (IQR) | 1.9 (0.1–4.9) | 1.0 (0.0–3.0) | 2.1 (0.4–5.3) | 0.02 |
Baseline cJADASb, median (IQR) | 3.0 (0.9–8.0) | 3.0 (1.0–6.0) | 4.5 (0.6–8.3) | 0.09 |
•Active Joint Countc | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.25 |
•Physician’s global assessmentd | 1.0 (0.0–3.0) | 0.0 (0.0–2.0) | 1.0 (0.0–3.0) | 0.07 |
•Patient/parent global assessmente | 1.8 (0.3–3.9) | 1.5 (0.0–3.0) | 1.9 (0.4–4.1) | 0.27 |
Baseline tender entheses countf, median (IQR) | 0.0 (0.0–2.0) | 0.0 (0.0–2.0) | 0.0 (0.0–1.0) | 0.11 |
HLA – B27 positiveg, n (%) | 62 (42) | 19 (36) | 43 (46) | 0.24 |
Polyarticular disease, n (%) | 42 (28) | 16 (31) | 26 (27) | 0.58 |
Sacroilitis confirmed by MRI (ever), n (%) | 42 (28) | 15 (28) | 27 (28) | 0.97 |
Biologic use (ever) | 101 (66) | 35 (65) | 66 (67) | 0.75 |
DMARD use (ever) | 58 (38) | 20 (37) | 38 (39) | 0.83 |